HL-085
HL-085 is a pharmaceutical drug with 9 clinical trials. Currently 1 active trials ongoing. Historical success rate of 60.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
4
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
60.0%
3 of 5 finished
40.0%
2 ended early
1
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
HL-085 in NRAS-mutated Advanced Melanoma
A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation
Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)
HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
Clinical Trials (9)
HL-085 in NRAS-mutated Advanced Melanoma
A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation
Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)
HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
Study of HL-085 in NRAS Mutant Advanced Melanoma
Study of HL-085 in Patients With Advanced Solid Tumor Tumors
Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC
Phase I Study of HL-085 in Patients With Advanced Solid Tumors
All 9 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 9